A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group

Trial Profile

A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2013

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Jun 2013 Planned end date changed from 1 Dec 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 08 Aug 2011 Planned end date changed from 1 Jun 2006 to 1 Dec 2011 as reported by ClinicalTrials.gov .
    • 22 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top